US FDA approves gene therapy for a rare neurological disorder

The US Food and Drug Administration (FDA) has approved bluebird bio's (BLUE.O) gene therapy for the treatment of a rare neurological disorder, the company said

Related Keywords

United States , ,Drug Administration ,Cerebral Adrenoleukodystrophy ,Fda ,Gene Therapy ,Neurological Disorder ,Latest ,World ,Tribune ,